High Tower Advisors, LLC Halozyme Therapeutics, Inc. Transaction History

High Tower Advisors, LLC

$84.5 Billion
Q3 2025

A detailed history of High Tower Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 26,138 shares of HALO stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,138

Previous 18,131 44.16%

Holding current value

$1.83 Million

Previous $943,000 103.18%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 06, 2025	BUY	$52.92 - $78.28 $423,730 - $626,787	8,007 Added 44.16%	26,138 $1.92 Million
Q2 2025 Aug 11, 2025	SELL	$47.91 - $70.14 $300,060 - $439,286	-6,263 Reduced 25.67%	18,131 $943,000
Q1 2025 May 12, 2025	BUY	$47.74 - $65.16 $372,372 - $508,248	7,800 Added 47.0%	24,394 $1.56 Million
Q4 2024 Feb 07, 2025	SELL	$42.57 - $61.09 $833,520 - $1.2 Million	-19,580 Reduced 54.13%	16,594 $793,000
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $311,647 - $391,351	6,075 Added 20.18%	36,174 $2.07 Million

Q2 2024 Aug 13, 2024	BUY	$37.81 - $52.4 $189,050 - $262,000	5,000 Added 19.92%	30,099 $1.58 Million
Q1 2024 May 06, 2024	SELL	$33.68 - $41.95 $287,020 - $357,497	-8,522 Reduced 25.35%	25,099 $1.02 Million
Q4 2023 Feb 12, 2024	BUY	$33.32 - $42.1 $487,571 - $616,049	14,633 Added 77.06%	33,621 $1.24 Million
Q3 2023 Nov 08, 2023	BUY	$36.46 - $44.03 $21,256 - $25,669	583 Added 3.17%	18,988 $725,000
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $17,047 - $21,810	563 Added 3.16%	18,405 $663,000
Q1 2023 May 11, 2023	SELL	$32.86 - $55.7 $2.38 Million - $4.04 Million	-72,510 Reduced 80.25%	17,842 $681,000
Q4 2022 Feb 08, 2023	SELL	$40.06 - $59.44 $238,477 - $353,846	-5,953 Reduced 6.18%	90,352 $5.14 Million
Q3 2022 Nov 09, 2022	BUY	$38.53 - $51.78 $3.12 Million - $4.19 Million	80,941 Added 526.82%	96,305 $3.82 Million
Q2 2022 Aug 10, 2022	BUY	$37.35 - $48.3 $127,438 - $164,799	3,412 Added 28.55%	15,364 $674,000
Q1 2022 May 12, 2022	BUY	$31.97 - $41.06 $25,959 - $33,340	812 Added 7.29%	11,952 $477,000
Q4 2021 Feb 10, 2022	BUY	$31.82 - $40.75 $47,889 - $61,328	1,505 Added 15.62%	11,140 $446,000
Q3 2021 Nov 12, 2021	SELL	$38.47 - $46.42 $19,965 - $24,091	-519 Reduced 5.11%	9,635 $391,000
Q2 2021 Aug 06, 2021	BUY	$38.84 - $51.31 $34,800 - $45,973	896 Added 9.68%	10,154 $461,000
Q1 2021 May 10, 2021	BUY	$39.51 - $51.45 $107,072 - $139,429	2,710 Added 41.39%	9,258 $387,000
Q4 2020 Feb 10, 2021	BUY	$25.81 - $43.62 $169,003 - $285,623	6,548 New	6,548 $281,000
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $427,430 - $559,124	-28,629 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$15.2 - $17.69 $7,600 - $8,845	-500 Reduced 1.72%	28,629 $443,000
Q2 2019 Aug 13, 2019	SELL	$14.75 - $17.26 $7,375 - $8,630	-500 Reduced 1.69%	29,129 $500,000
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $14,135 - $17,826	1,014 Added 3.54%	29,629 $476,000
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $20,781 - $29,090	1,559 Added 5.76%	28,615 $418,000
Q3 2018 Nov 09, 2018	BUY	$16.68 - $18.41 $95,192 - $105,065	5,707 Added 26.73%	27,056 $492,000
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $93,105 - $112,035	-5,519 Reduced 20.54%	21,349 $359,000
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $158,999 - $197,584	9,320 Added 53.11%	26,868 $527,000
Q4 2017 Feb 14, 2018	SELL	$16.75 - $20.8 $98,523 - $122,345	-5,882 Reduced 25.1%	17,548 $356,000
Q3 2017 Nov 14, 2017	SELL	$11.76 - $17.4 $134,287 - $198,690	-11,419 Reduced 32.77%	23,430 $407,000
Q2 2017 Aug 14, 2017	BUY	N/A	34,849	34,849 $446,000

Others Institutions Holding HALO

# of Institutions

666

Shares Held

128M

Call Options Held

626K

Put Options Held

455K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Account

High Tower Advisors, LLC Halozyme Therapeutics, Inc. Transaction History